Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GLP1R | P43220 | 8/20 | 0.46 |
| ▸ | TLR2 | O60603 | 4/20 | 0.46 |
| ▸ | SIRT6 | Q8N6T7 | 1/20 | 0.40 |
| ▸ | SIRT1 | Q96EB6 | 1/20 | 0.40 |
| ▸ | SLC6A5 | Q9Y345 | 1/20 | 0.39 |
| ▸ | NOD1 | Q9Y239 | 4/20 | 0.38 |
| ▸ | CCKAR | P32238 | 1/20 | 0.37 |
| ▸ | CCKBR | P32239 | 1/20 | 0.37 |
| ▸ | LPAR3 | Q9UBY5 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25604239 | 0.94 | GLP1R (0.46) | GLP1RTLR2SIRT6SIRT1SLC6A5 | |
| SCHEMBL24601556 | 0.84 | GLP1R (0.52) | GLP1RTLR2SLC6A5NOD1 | |
| SCHEMBL10046430 | 0.79 | TLR2 (0.63) | TLR2SIRT6SIRT1SLC6A5NOD1 | |
| SCHEMBL20366283 | 0.79 | NOD1 (0.61) | GLP1RSLC6A5NOD1 | |
| SCHEMBL14642510 | 0.78 | GLP1R (0.66) | GLP1RTLR2SIRT6SIRT1NOD1 | |
| SCHEMBL15085169 | 0.78 | GLP1R (0.66) | GLP1RTLR2SIRT6SIRT1NOD1 | |
| SCHEMBL15084764 | 0.78 | GLP1R (0.66) | GLP1RTLR2SIRT6SIRT1NOD1 | |
| SCHEMBL15085168 | 0.78 | GLP1R (0.66) | GLP1RTLR2SIRT6SIRT1NOD1 | |
| SCHEMBL15084765 | 0.78 | GLP1R (0.66) | GLP1RTLR2SIRT6SIRT1NOD1 | |
| SCHEMBL45887 | 0.78 | GLP1R (0.57) | GLP1RTLR2NOD1LPAR3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | CIDARA THERAPEUTICS, INC. | 2023-06-01 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230165970-A1 | COMPOSITIONS AND METHODS FOR THE TREATMENT OF BACTERIAL INFECTIONS | FCGR3B, FCGR1A, FCGR2A | GLP1R 3123/4885TLR2 78/4885SIRT6 4108/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.